Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
INVO FertilityIVF -8.37%35 EV-to-EBIT is -0.16 as of Jul. 18, 2026. GuruFocus rates IVF with a GF Score™ of 35/100 and a GF Value™ of $128.62 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 466 Medical Devices & Instruments companies, INVO Fertility ranks worse than 214592.06% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
INVO Fertility's Enterprise Value for the quarter that ended in Mar. 2026 was $3.87 Mil.
INVO Fertility's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INVO Fertility EV-to-EBIT Related Terms
INVO Fertility EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for INVO Fertility's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, INVO Fertility's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INVO Fertility EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, INVO Fertility's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where INVO Fertility's EV-to-EBIT falls into.
INVO Fertility's current Enterprise Value is $1.36 Mil.
INVO Fertility's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INVO Fertility (IVF) has a EV-to-EBIT of -0.16 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on INVO Fertility and its competitors. According to the industry distribution chart, INVO Fertility ranks #999999 out of 466 companies in the Medical Devices & Instruments industry.
Is INVO Fertility's EV-to-EBIT too high?
INVO Fertility's current EV-to-EBIT is -0.16. Based on the distribution chart, INVO Fertility ranks #999999 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, INVO Fertility has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does INVO Fertility's EV-to-EBIT compare to RMSL and ADMT?
According to the Medical Devices & Instruments industry distribution chart, INVO Fertility ranks #999999 out of 466 companies for EV-to-EBIT. This places INVO Fertility in the lower half of its industry. The industry median EV-to-EBIT is 18.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.46, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on INVO Fertility and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INVO Fertility's current EV-to-EBIT is -0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INVO Fertility stock overvalued right now?
Based on GuruFocus' analysis, INVO Fertility (IVF) is currently considered Possible Value Trap. The stock's GF Value™ is $128.62, compared to a current price of $1.05 — trading 99.2% below its estimated fair value. The current EV-to-EBIT is -0.16. INVO Fertility's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For INVO Fertility (IVF), the current EV-to-EBIT is -0.16 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INVO Fertility (IVF) Overvalued in 2026?
Based on GuruFocus' analysis, INVO Fertility stock appears to be undervalued.
The current stock price of $1.05 is trading 99.2% below its estimated GF Value™ of $128.62.
GuruFocus considers INVO Fertility to be Possible Value Trap.
Key valuation signals for IVF:
EV-to-EBIT: -0.16
GF Value™: $128.62 vs. price of $1.05 (99.2% below fair value)
No single metric tells the full story. See the IVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic and The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell.
35GF Score
Get the complete analysis for IVF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVF has been successfully added to your 
